Nolvadex BRCA1/2 Study IRB Approval Expected By October
Executive Summary
A breast cancer prevention study of Zeneca's Nolvadex (tamoxifen) in BRCA1 and 2 carriers could receive institutional review board approval by the end of the month, the National Surgical Adjuvant Breast and Bowel Project said.